MRD and Decision-Making in Early Stage Colorectal Cancer

Christopher Lieu, MD, discusses the standard of care for genomic profiling in early stage CRC.

Daniel Ahn, DO, reviews MRD as a novel approach to assessing risk for recurrence and response to treatment in early stage CRC.

A leader in diagnosis and management of CRC reviews the role of MRD testing in early stage CRC.

Dr. Daniel Ahn discusses the implications of postoperative ctDNA testing for decision-making in early stage CRC.

An expert in CRC describes key findings from clinical trials related to personalized detection of molecular recurrence in early stage CRC.

Dr. Christopher Lieu shares his insights into gaps in care in the adjuvant setting in colorectal cancer.

This article reviews MRD and decision-making in early-stage colorectal cancer and includes insights from Christopher Lieu, MD, of the University of Colorado School of Medicine in Denver, and Daniel Ahn, DO, of the Mayo Clinic in Phoenix, AZ.